Effect of Dachengqi decoction on NF-kappaB p65 expression in lung of rats with partial intestinal obstruction and the underlying mechanism.
To investigate the effect of Dachengqi decoction on NF-kappaB p65 expression in lung of rats with partial intestinal obstruction and the underlying mechanism, 30 SD rats were randomly divided into three groups: sham-operation group, model group and Dachengqi decoction treatment group (Dachengqi group), with 10 animals in each group. The models were made by partially ligating their large intestines outside the body. The pathological changes were analyzed by HE staining. The expression of NF-kappaB p65 in rats lung were measured by using real-time polymerase chain reaction and immunohistochemistry respectively. Moreover, the expression of caveolin-1 in rats lung was also measured to. Increased edema, interstitial thickening, hemorrhage, and infiltration of inflammatory cells were found in the model group. In contrast, this change was significantly reduced in Dachengqi group as compared with model group. In addition, the up-regulated caveolin-1 and NF-kappaB p65 were also suppressed by Dachengqi decoction in lung of rats with partial intestinal obstruction. We are led to concluded that the caveolin-1-NF-kappaB pathway plays an important role in the development of lung injury of rats with partial intestinal obstruction and Dachengqi decoction could down-regulate the expression of caveolin-1 and NF-kappaB p65 in lung of rats with partial intestinal obstruction.
Yang
Shenglan
S
Department of Traditional Chinese Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. yangshenglan@126.com
Shen
Lin
L
Jin
Yang
Y
Liu
Jianguo
J
Gao
Jiechang
J
Li
Daoben
D
D000818:Animals; D051242:Caveolin 1 / Q000235:genetics / Q000378:metabolism; D015536:Down-Regulation; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000378:metabolism; D008168:Lung / Q000378:metabolism*; D055370:Lung Injury / Q000517:prevention & control; D008297:Male; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*
C495537:Cav1 protein, rat; D051242:Caveolin 1; D010936:Plant Extracts; D012333:RNA, Messenger; C498145:Rela protein, rat; D051996:Transcription Factor RelA; C477169:dachengqi decoction
J Huazhong Univ Sci Technolog Med Sci. 2004;24(5):528-30
15641712
Mol Cell Biol. 2003 Nov;23(22):8070-83
14585967
Science. 2002 Apr 19;296(5567):535-9
11964480
Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L187-96
12471015
Mol Cell. 2003 Oct;12(4):829-39
14580335
Intensive Care Med. 1998 Nov;24(11):1131-8
9876974
Am J Surg. 1999 Dec;178(6):449-53
10670850
J Immunol. 2002 Nov 1;169(9):5287-93
12391248
Am J Physiol Lung Cell Mol Physiol. 2004 Jul;287(1):L143-52
15047567
Clin Cancer Res. 2004 Aug 15;10(16):5501-7
15328189
J Biol Chem. 1997 Nov 28;272(48):30429-38
9374534
J Biol Chem. 2002 Mar 8;277(10):8635-47
11739396
Annu Rev Cell Biol. 1994;10:405-55
7888182
J Immunol. 2006 Oct 1;177(7):4853-60
16982927
Blood. 2007 Jan 15;109(2):653-60
17008547
Chin J Integr Med. 2006 Jun;12(2):122-5
16800991
Eur J Cardiothorac Surg. 2005 Jan;27(1):23-7
15621466
J Immunol. 2006 Apr 15;176(8):4995-5005
16585596
Eur Surg Res. 2008;40(2):184-9
17998777
J Immunol. 2001 Aug 1;167(3):1592-600
11466381
Nat Rev Immunol. 2002 Oct;2(10):725-34
12360211
Annu Rev Immunol. 1996;14:649-83
8717528
World J Surg. 1996 May;20(4):411-7
8662128
J Biol Chem. 2005 Jul 1;280(26):25134-45
15802273
J Immunol. 2003 Jan 15;170(2):1091-8
12517978
Am J Respir Cell Mol Biol. 2007 Jun;36(6):645-53
17218616
Am J Respir Cell Mol Biol. 1997 Jul;17(1):3-9
9224203